Prospects for managing patients with stable atherosclerosis
AbstractLong-term management of patients with stable atherosclerosis is regulated by current clinical guidelines, but until now some treatment aspects remain unclear. This paper presents applicability of combined anti-thrombotic (anti-platelet and anticoagulant) therapy, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors; brief review of randomized clinical trials examining efficacy and safety of these drugs is given; indications field are estimated; controversial issues of their administration are being looked at.
Keywords:atherosclerosis, ischemic heart disease, peripheral vascular disease, rivaroxaban, PCSK9, SGLT2
Cardiology: News, Opinions, Training. 2018; 6 (2): 9-14. doi: 10.24411/2309-1908-2018-12001